AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03549689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current tenofovir alafenamide (TAF)-containing ART regimen
Description: Continuation of current TAF-containing ART for 96 weeks.
Study NCT04071002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks physical therapy programme
Description: The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
Study NCT06148129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Biopsy
Description: The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
Study NCT00650468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study NCT00650468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: IV or Oral
Study NCT00650468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids (methylprednisone or prednisone)
Description: IV or Oral
Study NCT03584594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Presepsin measurement
Description: Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
Study NCT03022851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlutech AFR Device
Description: Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
Study NCT01231698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmolol
Description: Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
Study NCT01231698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: standard treatment without strict heart rate control
Study NCT04424368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The remote monitoring system
Description: Usage of remote monitoring system
Study NCT03117335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)
Study NCT03117335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulijia
Description: Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)
Study NCT02344186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Crossover design - 24 weeks on active drug and 12 weeks daily placebo
Study NCT02344186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Crossover design - 24 weeks on active drug and 12 weeks daily placebo
Study NCT00889122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame (DDR)
Description: Use of an active videogame vs. pedometers given to entire families to promote physical activity.
Study NCT04241939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numberless BDS
Description: Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
Study NCT04241939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scale
Description: Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
Study NCT04241939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Motivational Interviewing
Description: Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
Study NCT03290716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SS
Description: Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
Study NCT03290716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSSC
Description: A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
Study NCT02264223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented red clover isoflavones in aglycone form
Description: Fermented isoflavones in aglycone form
Study NCT02264223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unfermented glycosides (as aglycone equivalents)
Description: Unfermented aglycone equivalents in glycoside form
Study NCT01525082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine by mouth twice daily on Days 1 to 14
Study NCT01525082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide by mouth daily on Days 10 to 14
Study NCT01525082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
Study NCT03783923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
Study NCT03906773 — intervention group
Intervention type: OTHER
Intervention: Patient Centered Medical Home Based Electronic Framework for Advance Care Planning
Description: The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
Study NCT03987737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small urinary catheter placement in the rectum
Description: The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
Study NCT02432456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Block
Description: All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
Study NCT02432456 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intercostal Nerve Block
Description: All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methocarbamol
Description: All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methocarbamol
Description: All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
Study NCT02432456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
Study NCT01926301 — intervention group
Intervention type: PROCEDURE
Intervention: continuous veno-venous hemodialysis
Study NCT04169425 — intervention group
Intervention type: PROCEDURE
Intervention: elective diverting ileostomy
Study NCT03461029 — intervention group
Intervention type: DEVICE
Intervention: BIS monitor
Description: The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
Study NCT01400373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prehospital intra-nasal cooling with RhinoChill
Description: Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
Study NCT02534207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
Study NCT04333199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timely
Description: Email
Study NCT02822937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
Study NCT02822937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Description: Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
Study NCT02822937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project: EVO
Description: Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
Study NCT02822937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill
Study NCT02391922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First aid course
Study NCT04333199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transparency
Description: Email
Study NCT04125693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
Study NCT04333199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot-in-the-door
Description: Email
Study NCT00116129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutamoren Mesylate (MK-0677)
Description: Ibutamoren Mesylate 25 mg/day
Study NCT02554344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
Study NCT03273712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA tyr3-Octreotide
Description: 90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
Study NCT03273712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan
Description: 68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
Study NCT03273712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
Study NCT01900392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
Study NCT03300232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based VC-CBT
Description: Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
Study NCT03142893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin Injectable Product
Description: cosyntropin injection is given twice per Inpatient Stay
Study NCT04242368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
Study NCT04242368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
Study NCT04242368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Nasal Wash
Description: Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
Study NCT04242368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Nasal Wash
Description: Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
Study NCT04242368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone nasal spray administered two sprays to each nare twice a day
Study NCT04242368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Fluticasone nasal spray administered two sprays to each nare twice a day
Study NCT03142893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Luteinizing Hormone
Description: Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
Study NCT03142893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Injection
Description: Hydrocortisone IV push is given twice per Inpatient Visit
Study NCT04125693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
Study NCT02992639 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The participants who included in control group did not receive any treatment.
Study NCT02992639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss group
Description: The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
Study NCT04504877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol 300 mg daily for 4 weeks
Study NCT04504877 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol
Description: Cannabidiol 300 mg daily for 4 weeks
Study NCT04483453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXPL feeding regimen
Description: EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
Study NCT04483453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTRL feeding regimen
Description: CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
Study NCT01103206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet
Description: Intake of a single tablet of cinacalcet
Study NCT01103206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet dose 1
Description: PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
Study NCT01103206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet dose 2
Description: Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
Study NCT01887431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare
Description: Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
Study NCT01531062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sative
Description: Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
Study NCT01887431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: 3-month routine clinic visits
Study NCT01531062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: black sticky rice
Description: 300 mg capsule bid, 56 days
Study NCT02936479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-INH (Berinert)